Stayble Therapeutics AB — Investor Relations & Filings

Stayble Therapeutics is a clinical-stage pharmaceutical company developing treatments for chronic pain originating from spinal disc conditions. The company's lead drug candidate, STA363, is a minimally invasive, single-injection formulation for intradiscal administration. It is designed to treat chronic low back pain and leg pain (sciatica) caused by disc degeneration and lumbar disc herniation (LDH). STA363 is positioned as a second-line therapy for patients who have not found relief from conservative treatments such as physiotherapy and analgesics, offering an alternative to surgery. The treatment aims to provide long-term pain relief by transforming the disc's nucleus pulposus into connective tissue, thereby stabilizing the disc and reducing pain-causing leakage. The company is advancing STA363 through clinical development to validate its safety and efficacy.